Gilead’s Kite flies higher as Yescarta leads CAR-T therapy class to earlier lymphoma treatmentnews2022-03-31T16:16:44+00:00March 31st, 2022|Fierce Pharma|
Boehringer goes bold with ‘unwearable’ fashion to spotlight patients’ rare skin disease painnews2022-03-31T14:22:26+00:00March 31st, 2022|Fierce Pharma|
Preparing manufacturers for a changing copay landscapenews2022-03-31T13:52:17+00:00March 31st, 2022|Fierce Pharma|
Feds probe ring of counterfeit HIV meds targeting Gilead, GlaxoSmithKline and Johnson & Johnson: reportnews2022-03-31T13:49:23+00:00March 31st, 2022|Fierce Pharma|
Targeting GSK and AstraZeneca, Clovis lifts sinking Rubraca with broad ovarian cancer winnews2022-03-31T13:24:21+00:00March 31st, 2022|Fierce Pharma|
Bayer sheds some sites in €2B push to expand next-gen manufacturing capabilitiesnews2022-03-31T12:16:41+00:00March 31st, 2022|Fierce Pharma|
Novavax, hoping to bump up its lagging European launch, asks EMA to authorize its COVID shot in teenagersnews2022-03-31T11:13:12+00:00March 31st, 2022|Fierce Pharma|
Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exitnews2022-03-31T08:39:26+00:00March 31st, 2022|Fierce Pharma|
‘Extreme disappointment’: With FDA snub of Akebia’s vadadustat, another oral anemia med bites the dustnews2022-03-31T01:47:22+00:00March 31st, 2022|Fierce Pharma|
Senate blesses bill to wrest US supply chains from China’s grasp, with pharma front and centernews2022-03-30T19:54:35+00:00March 30th, 2022|Fierce Pharma|
